AstraZeneca's ASTER Study: Real-World Insights into Anifrolumab's Efficacy in SLE Treatment

AstraZeneca's ASTER study aims to evaluate the real-world effectiveness and quality of life outcomes for patients with Systemic Lupus Erythematosus (SLE) receiving anifrolumab. The study is a prospective, observational cohort study that began in February 2023 and is currently recruiting participants. The findings could significantly impact AstraZeneca's stock performance and influence market dynamics in the competitive SLE treatment landscape.